Ervebo (Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live))
PRIME
- Region
- 🇪🇺 EU
- Active substance
- Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live)
- Company
- Merck Sharp & Dohme B.V.
- Status
- Authorised
- Therapeutic area
- Hemorrhagic Fever, Ebola
- CHMP opinion
- Thu 17 Oct 2019
- EU approval
- Mon 11 Nov 2019
- Designations
- PRIME
- Application
- EMEA/H/C/004554
- Official record
- www.ema.europa.eu
Indication
Ervebo is indicated for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus. The use of Ervebo should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Follow Ervebo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.